FDA Drugs (New Approvals & NDA)Original article
Non-Compliance Letters under 505B(d)(1) of the Federal Food, Drug, and Cosmetic Act
RegulatoryNeutral
AI Analysis
Summary
FDA guidance on Non-Compliance letters issued to sponsors who fail to submit required pediatric assessments under PREA regulations by specified deadlines.
Outcome Details
FDA sends Non-Compliance letters to sponsors who fail to submit pediatric assessments required under PREA by final due date or fail to seek/obtain deferral
Importance:3/10
Sentiment:
0.00
PREAPediatric AssessmentFDA Compliance505B(d)(1)Regulatory
Read the original article
Published by FDA Drugs (New Approvals & NDA) on September 25, 2026 6:49 PM